Related Experiment Video
Updated: Mar 25, 2026
The Forced Swim Test as a Model of Depressive-like Behavior
Published on: March 2, 2015
Examining Endothelial Function and Platelet Reactivity in Patients with Depression before and after SSRI Therapy
Tye Dawood1, David A Barton2, Elisabeth A Lambert3
1Human Neurotransmitters Laboratory, Baker IDI Heart & Diabetes Institute , Melbourne, VIC , Australia.
Insights
Major depressive disorder (MDD) patients treated with serotonin-specific reuptake inhibitors (SSRIs) showed reduced depression symptoms but no change in endothelial function. Baseline noradrenaline levels predicted SSRI treatment response.
Area of Science:
- Cardiovascular Medicine
- Neuroscience
- Pharmacology
Background:
- Major depressive disorder (MDD) is linked to increased cardiovascular disease (CVD) risk.
- Endothelial dysfunction is an early indicator of CVD.
- Mechanisms connecting MDD and CVD risk are not fully understood.
Purpose of the Study:
- To investigate the impact of serotonin-specific reuptake inhibitor (SSRI) therapy on endothelial function in patients with MDD.
- To assess changes in vascular and platelet reactivity markers during SSRI treatment.
- To identify predictors of SSRI treatment response in MDD patients.
Main Methods:
- Assessed endothelial function using flow-mediated dilatation and laser Doppler velocimetry in 31 MDD patients before and after SSRI therapy.
- Measured plasma levels of intercellular adhesion molecule-1, vascular cell adhesion molecule-1, soluble P-selectin, and noradrenaline.
- Evaluated depression symptom severity using the Hamilton Rating Scale.
Main Results:
- SSRI therapy significantly reduced depression symptoms (P < 0.001) with 19 patients recovered and 4 remitted.
- No significant changes were observed in endothelial function, vascular markers, or platelet reactivity post-SSRI treatment.
- Baseline noradrenaline concentration independently predicted improvement in depression symptoms (r² = 0.36, P = 0.003), with lower levels in responders.
Conclusions:
- SSRI therapy effectively alleviates depression symptoms in MDD patients.
- SSRI treatment did not alter endothelial function or vascular/platelet markers in this cohort.
- Pre-treatment noradrenaline levels may predict SSRI treatment efficacy in MDD.
Abstract:
Although it is recognized that patients with major depressive disorder (MDD) are at increased risk of developing cardiovascular disease (CVD) the mechanisms responsible remain unknown. Endothelial dysfunction is one of the first signs of CVD. Using two techniques, flow-mediated dilatation in response to reactive hyperemia and laser Doppler velocimetry with iontophoresis, we examined endothelial function in the forearm before and after serotonin-specific reuptake inhibitor (SSRI) treatment in 31 patients with MDD. Measurement of intercellular adhesion molecule-1, vascular cell adhesion molecule-1, soluble P-selectin, and noradrenaline in plasma was also performed. Prior to treatment, markers of endothelial and vascular function and platelet reactivity were within the normal range. Following SSRI therapy (95 ± 5 days) symptoms of depression were reduced (paired difference between pre- and post-treatment Hamilton rating -18 ± 1, P < 0.001) with 19 patients recovered and 4 remitted. There occurred no significant change in markers of endothelial or vascular function following SSRI therapy. The improvement in Hamilton depression rating in response to therapy could be independently predicted by the baseline arterial plasma noradrenaline concentration (r (2) = 0.36, P = 0.003). In this cohort of patients with MDD, SSRI therapy did not influence endothelial function or markers of vascular or platelet reactivity. Patient response to SSRI therapy could be predicted by the initial circulating level of noradrenaline, with noradrenaline levels being lower in responders.
Related Concept Videos
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
01:23Antidepressant Drugs: MAOIs and Other Agents
01:21G-protein Coupled Receptors
01:25Antidepressant Drugs: Overview